@ash.hematology.orgThe 2027 Highlights of ASH are coming to cities around the world!
Following #ASH26, leading experts will explore what the latest #ASH26 findings mean for clinical practice and patient care in your region.
Register today: https://ow.ly/5pms50ZTtI7
@ash.edu.hematology.org🎧 New Episode Alert! 🎧🎙️ Listen now to the new episode of HemeTalks: Conversations in Hematology Education on From Aplastic Anemia to PNH: The Patient Perspective! #HemeTalks #MedicalPodcast #Hematology
@hemehub.bsky.socialExplore the latest insights on Acute Intermittent Porphyria with Dr. Karl E. Anderson and Dr. Taha Bat in our upcoming live webinar!
⮕ Register: hemehub.org/live-webinars
⮕ Submit your cases: hemehub.org/case-submiss...
#AcuteIntermittentPorphyria #AIP #Porphyria #RareDiseases #Hematology
@drtimos.bsky.socialHow to win in #Oncology and #Hematology in 2025
📥 Get a FREE #LucidQuest Report http://dlvr.it/TVhmxL
🚀 Oncp/hema drug development is evolving fast. AI-driven Dx, novel MoAs & outcomes-based pricing are reshaping the landscape.
🏆 Who’s leading? AbbVie, Amgen, AZ, BMS, J&J & Novartis.
@talhabadarmd.bsky.social🧠 CNS prophylaxis remains essential in ALL, especially as therapy becomes chemo-attenuated or chemo-free. Blinatumomab/inotuzumab do not replace CNS-directed therapy. Modern regimens often use 12–15 IT treatments, tailored to regimen and risk. #ALL #Leukemia #Hematology
@sigtrans-sttt.bsky.socialResearchers show that targeting BIRC6 disrupts a Treg-driven pathway that supports aged HSC survival, helping rebalance #hematopoiesis, reduce #Immunosenescence, and improve immune function in models of #Aging.
#STTT #OpenAccess: doi.org/10.1038/s413...
#Hematology #Immunology
@theebmt.bsky.social🔎 Discover September's Top Picks from Bone Marrow Transplantation, the official journal of EBMT: https://www.ebmt.org/ebmt/news/top-picks-bone-marrow-transplantation-7
@hemehub.bsky.social🩸🔍 Today’s questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #HemeHub
@societyofhemonc.bsky.socialRegistration is open for the 4th SOHO-Israel Meeting & 10th International Davidoff Conference, Nov 19–20, 2026, in person or online.
Register: hematology2026.forms-wizard.biz
Read more: sohoinsider.com/news/4th-soh...
@ashclinicalnews.bsky.socialComplement activation. Chronic inflammation. Shared mechanisms across cytopenias.
In a free webinar, learn how a pathway-based approach can sharpen your clinical management of #ITP, #wAIHA, and beyond.
📅 Sept 30 · 10 AM EDT
Register at 👇
https://ow.ly/ck1s50ZPIfv
@onclive.bsky.socialAn observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies. #hematology #oncology
Learn more ➡️: www.onclive.com/view/orca-t-...
@hemehub.bsky.social💭🎯 Today’s questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #MRD #ASCT #StemCellTransplant #APOBEC #HemeHub
@hemehub.bsky.social🧬 Facts about Smoldering Multiple Myeloma:
Genomic MM vs. genomic MGUS, genomic drivers of progression, genomic biomarkers of non-progressors, the Genomic Scar Score (GSS), and the continuous genomic gradient from MGUS to SMM to MM.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology
@hemehub.bsky.social🩸 Join us for an upcoming live webinar with Karl E. Anderson, MD and Taha Bat, MD on Acute Intermittent Porphyria, featuring case-based discussions and real-world clinical perspectives.
⮕ Register: hemehub.org/live-webinars
#AcuteIntermittentPorphyria #AIP #Porphyria #RareDiseases #Hematology
@ash.hematology.orgJoin the ASH Journal Club on Sept. 22 for a discussion with Blood Journals Portfolio study authors about their iPSC-derived bone marrow organoid technology.
Save your spot! https://ow.ly/V7Ht50ZPkNP
@onclive.bsky.social“We can tailor treatment and make nuanced decisions for the individual patient in front of us,” Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, of @petermaccc.bsky.social said of CLL management. @societyofhemonc.bsky.social #SOHO2026 #lymsm #hematology
Full interview: www.onclive.com/view/cll-tre...
@onclive.bsky.socialReady for The Five Under 5 🕘? Here is your go-to roundup of the top 5 #OncLiveTV 📹 videos of last week. @danafarber.bsky.social @mdanderson.bsky.social @ucdavis.bsky.social #hematology #oncology
Watch the clips that made the list 🔗: www.onclive.com/view/five-un...
@drtimos.bsky.socialHow to win in #Oncology and #Hematology in 2025
📥 Get a FREE #LucidQuest Report http://dlvr.it/TVYrKq
🚀 Oncp/hema drug development is evolving fast. AI-driven Dx, novel MoAs & outcomes-based pricing are reshaping the landscape.
🏆 Who’s leading? AbbVie, Amgen, AZ, BMS, J&J & Novartis.
@tenuretracker.bsky.socialThe Ohio State University is hiring:
Research Associate 1 in Hematology